Finch Therapeutics (NASDAQ:FNCH) stock is rising higher on Friday following news that the U.S. Food and Drug Administration (FDA) has released its clinical hold on CP101.
CP101 is Finch Therapeutics’ investigational new drug designed to prevent recurrent C. difficile infection. The clinical hold was on the company’s application for this drug. This will allow it to move forward with a Phase 3 clinical trial of the treatment.
So what’s behind the end of the clinical hold on CP101? The FDA released its hold on the drug after a review from Finch Therapeutics. That covered its SARS-CoV-2 screening procedures, as well as associated informed consent language.
According to Finch Therapeutics, it will move forward with its PRISM4 clinical trial after completing requirements in manufacturing and quality connected to the FDA hold. The company intends to update shareholders when it has the timing for the clinical trial down.
Mark Smith, PhD, CEO of Finch Therapeutics, said the following in the press release sending FNCH stock higher.
“We look forward to completing the additional activities that we believe will enable us to proceed with enrollment in PRISM4, our Phase 3 study of CP101 in recurrent C. difficile infection, and we thank our PRISM4 trial partners for their continued support and dedication to serving patients who are battling recurrent C. difficile infection.”
It’s worth pointing out that the rally of FNCH stock today comes after almost of week of retreats. That was tied to the company cutting 20% of its workforce and shifting focus to different medicines.
FNCH stock is up 32.8% as of Friday afternoon.
Investors roving for more stock market news will want to keep reading!
We’ve got all the hottest stock news that traders need to know about for Friday! Among that is all of the latest news concerning shares of Apple (NASDAQ:AAPL) stock, Tesla (NASDAQ:TSLA) stock, and Chinese EV stocks. You can find out all about these matters at the following links!
More Friday Stock Market News
On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com’s writers disclose this fact and warn readers of the risks.
Read More: Penny Stocks — How to Profit Without Getting Scammed